These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Oxidation of low-density lipoproteins in renal transplant recipients treated with tacrolimus. Cofan F; Zambon D; Laguna JC; Ros E; Casals E; Cofan M; Campistol JM; Oppenheimer F Transplant Proc; 2002 Feb; 34(1):377-8. PubMed ID: 11959335 [No Abstract] [Full Text] [Related]
4. Low-density lipoprotein composition and oxidation are not influenced by calcineurin inhibitors in renal transplant patients. Morena M; Vela C; Garrigue V; Catanzano J; Descomps B; Cristol JP; Mourad G Transplant Proc; 2000 Dec; 32(8):2785-6. PubMed ID: 11134805 [No Abstract] [Full Text] [Related]
5. Low-density lipoprotein oxidizability and the alteration of its fatty acid content in renal transplant recipients treated with cyclosporine/tacrolimus. Bakar F; Keven K; Dogru B; Aktan F; Erturk S; Tuzuner A; Erbay B; Nebioglu S Transplant Proc; 2009 Jun; 41(5):1630-3. PubMed ID: 19545695 [TBL] [Abstract][Full Text] [Related]
6. Effect of calcineurin inhibitors on low-density lipoprotein oxidation. Cofan F; Cofan M; Campos B; Guerra R; Campistol JM; Oppenheimer F Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540 [TBL] [Abstract][Full Text] [Related]
7. Fatty acid composition of low-density lipoprotein in renal transplant recipients treated with cyclosporine. Cofan F; Zambon D; Laguna JC; Ros E; Casals E; Cofan M; Campistol JM; Oppenheimer F Transplant Proc; 2002 Feb; 34(1):374-6. PubMed ID: 11959334 [No Abstract] [Full Text] [Related]
8. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. Varghese Z; Fernando RL; Turakhia G; Psimenou E; Brunton C; Fernando ON; Davenport A; Burns A; Sweny P; Powis SH; Moorhead JF Transplant Proc; 1998 Aug; 30(5):2043-6. PubMed ID: 9723384 [No Abstract] [Full Text] [Related]
9. Conversion from cyclosporine to tacrolimus in renal allograft recipients with delayed graft function from severe acute tubular necrosis. Jang HJ; Kim SC; Han DJ Transplant Proc; 2000 Nov; 32(7):1714-5. PubMed ID: 11119904 [No Abstract] [Full Text] [Related]
10. [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation]. Martínez Castelao A; Ramos R; Serón D; Gil-Vernet S; Fiol C; Gómez-Gerique N; Yzaguirre MT; Hurtado I; Sabaté I; Alsina J; Grinyó JM Nefrologia; 2002; 22(4):364-9. PubMed ID: 12369128 [TBL] [Abstract][Full Text] [Related]
11. One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine. El Haggan W; Barthe N; Vendrely B; Chauveau P; Berger F; Aparicio M; Potaux L Transplant Proc; 2002 Aug; 34(5):1817-8. PubMed ID: 12176589 [No Abstract] [Full Text] [Related]
12. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Busque S; Demers P; St-Louis G; Boily JG; Tousignant J; Lemieux F; Smeesters C; Corman J; Daloze P Transplant Proc; 1998 Jun; 30(4):1247-8. PubMed ID: 9636507 [No Abstract] [Full Text] [Related]
13. Clinical study of FK 506 in renal transplant recipients. Youhua Z; Zhinlian M; Liming W Transplant Proc; 2000 Nov; 32(7):1704. PubMed ID: 11119900 [No Abstract] [Full Text] [Related]
14. Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. Claesson K; Mayer AD; Squifflet JP; Grabensee B; Eigler FW; Behrend M; Vanrenterghem Y; van Hooff J; Morales JM; Johnson RW; Buchholz B; Land W; Forsythe JL; Neumayer HH; Ericzon BG; Mühlbacher F Transplant Proc; 1998 Jun; 30(4):1292-4. PubMed ID: 9636524 [No Abstract] [Full Text] [Related]
15. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076 [TBL] [Abstract][Full Text] [Related]
16. High QT dispersion in tacrolimus-treated kidney transplant recipients. Gerhardt U; Suwelack B; Pawolka A; Hohage H Transplant Proc; 2001 May; 33(3):2148-50. PubMed ID: 11377482 [No Abstract] [Full Text] [Related]
17. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients. Blume C; Hollenbeck M; Ivens K; Heering P; Hetzel GR; Grabensee B Transplant Proc; 2001; 33(7-8):3161-3. PubMed ID: 11750357 [No Abstract] [Full Text] [Related]
18. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495 [No Abstract] [Full Text] [Related]
19. Tacrolimus and glucose metabolism. van Hooff JP; van Duijnhoven EM; Christiaans MH Transplant Proc; 1999 Nov; 31(7A):49S-50S. PubMed ID: 10576044 [No Abstract] [Full Text] [Related]
20. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. Maes BD; Vanwalleghem J; Kuypers D; Ghoos Y; Rutgeerts PJ; Vanrenterghem YF Transplantation; 1999 Nov; 68(10):1482-5. PubMed ID: 10589943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]